ETHZilla Corporation Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lloyd Blair Jordan
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 4 Palo Alto CA United States of America 94306
- IPO Date
- Jun 27, 2017
- CIK
- 0001690080
- Website
- 180lifesciences.com
- Similar Companies
- Business
- ETHZilla Corporation (Nasdaq: ETHZ), formerly 180 Life Sciences Corp., operates as a technology company focused on Ethereum treasury management and decentralized finance infrastructure, accumulating and deploying Ether (ETH) through staking, restaking, and onchain yield strategies; it maintains legacy biotechnology assets targeting inflammation, fibrosis, and pain with programs including anti-TNF therapies for Dupuytren’s contracture, frozen shoulder, and liver fibrosis, synthetic CBD analogs for arthritis and pain, and orally bioavailable anti-TNF for ulcerative colitis, alongside gaming initiatives. The company, founded in 2020 and headquartered in Palm Beach, Florida, connects financial institutions and organizations worldwide via Ethereum protocol implementations, offering tokenization solutions, DeFi protocol integration, blockchain analytics, and asset digitization across Layer 2 networks. In recent developments, ETHZilla rebranded from 180 Life Sciences and changed its ticker from ATNF to ETHZ in August 2025, accumulating over 102,000 ETH valued at approximately $443 million at an average acquisition cost of $3,949 per ETH; it raised $425 million in a private placement and $350 million in convertible debentures led by institutional investors including Polychain Capital and Electric Capital, closed $156 million in convertible notes, initiated partnerships with Electric Capital, Puffer for $47 million ETH restaking, and EtherFi for $100 million deployment, launched a $250 million stock repurchase program buying back millions of shares at discounts to net asset value, executed a 1-for-10 reverse stock split in October 2025, appointed McAndrew Rudisill as CEO and Jason New to its board, and reported Q3 2025 staking yield revenue amid ongoing ETH yield allocations and treasury optimization.
Stock Market Today: S&P 500, Nasdaq 100 Futures Trade Mixed— UnitedHealth, 180 Life Sciences, Intel In Focus
Palantir co-founder Peter Thiel buys into crypto firm as stock soars 250%
180 Life Sciences (ETHZilla) Holds 82,186 ETH
180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes
180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy
180 Life Sciences Announce an Upsized $425 Million Private Placement to Establish an Ether Treasury Reserve Led by Consortium of Digital Asset Leaders to Launch ETHZilla
180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets
180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction
180 Life Sciences Corp. Announces Share Repurchase
180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules
180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules
180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
180 Life Sciences Corp. - Corporate Updates
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement